Roswell Park Comprehensive Cancer Center (Roswell Park) believes it is in a unique position to lead innovative immune-oncology clinical research. The Center for Immunotherapy at Roswell Park is product to be among only 28 elite universities and cancer centers in North America that make up the Cancer Immunotherapy Trials Network (CITN). This means access to more treatment options for cancer patients in need.
A Unique Position
Richard Koya, MD, PhD, Associate Director, Center for Immunotherapy Director, Vector Development & Production Facility discusses why Roswell Park finds itself in a unique position. With a leadership position in CAR-T cell therapy, Roswell Park has accelerated new innovative cell therapies from the lab into the clinic. In fact, in 2017, they opened up two clinical trials based on T cell therapies and in 2018 they open many more trials.
On a Mission
Roswell Park Center for Immunotherapy was one of the first centers in America to combine patient care, research laboratories and state-of-the-art core facilities in one immunotherapy program. This unique approach supports compelling early entry Phase I and Phase II cancer immunotherapy clinical trials—bolstering their mission to bring innovative therapies from the lab to the patient while minimizing barriers and limitations.
Roswell Park includes patient stories showcasing the their FDA-approved CAR T-cell therapy work around Yescarta™ (large B-cell lymphoma) and Kymriah™ (acute lymphoblastic leukemia/ALL and large B-cell lymphoma that has relapsed or is refractory).
Call to Action: Seeking to potentially participate in Roswell Park clinical trials? See the eligibility link here.